ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Cyclic enaminone as new chemotype for selective cyclooxygenase-2 inhibitory, anti-inflammatory, and analgesic activities

Kumar, Raj; Saha, Nirjhar; Purohit, Priyank; Garg, Sanjeev K.; Seth, Kapileswar; Meena, Vachan S.; Dubey, Sachin; Dave, Khyati; Goyal, Rohit; Sharma, Shyam S.; Banerjee, Uttam C.; Chakraborti, Asit K.*
European Journal of Medicinal Chemistry2019-11-15DOI: 10.1016/j.ejmech.2019.111601
33被引4阅读
引用收藏
分享

摘要

The cyclic enaminone moiety has been identified as a new scaffold for selective inhibition of cyclooxygenase-2 with anti-inflammatory and analgesic activities. The designed cyclic enaminones have been synthesized conveniently through the development of a new catalyst-free methodology and evaluated for cyclooxygenase (COX-1 and COX-2) inhibitory activities. Three compounds 7d, 8, and 9 predominantly inhibited COX-2 with selectivity index of 74.09, 19.45 and 108.68, respectively, and were assessed for in vivo anti-inflammatory activity in carrageenan induced rat paw edema assay. The anti-inflammatory activity of 7d was comparable to that of celecoxib at a dose of 12.5 mg/kg. However, the compounds 8 and 9 were more/equally effective as anti-inflammatory agent compared to celecoxib at the doses of 12.5 mg/kg and 25 mg/kg and also exhibited anti-inflammatory activity comparable to that of diclofenac. The therapeutic potential of the most active compound 9 was further assessed by performing in vivo thermal and mechanical hyperalgesia tests using various models that revealed its analgesic activity. The in vivo non-ulcerogenicity of 9 revealed the gastrointestinal safety as compared to the nonselective COX inhibitor indomethacin. The in vitro antioxidant activity and in vivo experiments on heart rate and blood pressure provided the cardiovascular safety profile of 9. The molecular docking studies rationalize the COX-2 selectivity of the newly found anti-inflammatory compounds 7d, 8, and 9.

学科与关键词

关键词
Cyclic enaminoneCatalyst free novel methodologyNew anti-inflammatory chemotypesAnalgesic activityGastrointestinal and cardiovascular safety evaluation
相关
加载中…
  • Synthesis, anti-inflammatory screening, molecular docking, and COX-1,2/-5-LOX inhibition profile of some novel quinoline derivatives
    Chaaban, Ibrahim; Rizk, Ola H.*; Ibrahim, Tamer M.; Henen, Shery S.; El-Khawass, Sayeda M.; Bayad, Aida E.; El-Ashmawy, Ibrahim M.; Nematalla, Hisham A.Bioorganic Chemistry, 2018, 78: 220-235.被引 33
  • Pharmacophore model, docking, QSAR, and molecular dynamics simulation studies of substituted cyclic imides and herbal medicines as COX-2 inhibitors
    Moussa, Nathalie*; Hassan, Ahmad*; Gharaghani, SajjadHeliyon, 2021, 7(4): e06605.被引 16
  • Design, synthesis and biological evaluation of new tricyclic spiroisoxazoline derivatives as selective COX-2 inhibitors and study of their COX-2 binding modes via docking studies
    Abolhasani, Hoda; Dastmalchi, Siavoush; Hamzeh-Mivehroud, Maryam; Daraei, Bahram; Zarghi, Afshin*MEDICINAL CHEMISTRY RESEARCH, 2016, 25(5): 858-869.被引 15
查看全部 →

发表信息

论文状态
公开发表
期刊
European Journal of Medicinal Chemistry
发表日期
2019-11-15
卷期
第 182 卷
页码
111601
DOI
10.1016/j.ejmech.2019.111601
语言
MULTI-LANGUAGE
成果收录
SCIE
资助标注
University Grant Commission, New Delhi; Department of Science and Technology (New Delhi, India) [SR/S1/OC-33/2008]

作者

  • K

    Kumar, Raj (第一作者)

  • S

    Saha, Nirjhar

查看全部 12 位作者收起作者
  • P

    Purohit, Priyank

  • G

    Garg, Sanjeev K.

  • S

    Seth, Kapileswar

  • M

    Meena, Vachan S.

  • D

    Dubey, Sachin

  • D

    Dave, Khyati

  • G

    Goyal, Rohit

  • S

    Sharma, Shyam S.

  • B

    Banerjee, Uttam C.

  • C

    Chakraborti, Asit K. (通讯)

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417